Lisa Carter commenced working in the AOD Sector in 2001. Lisa has worked in community development, and as a Community Drug and Alcohol Worker specialising in issues for prisoners and families of prisoners, with an interest in health promotion and social justice, she has worked with many clients affected by hepatitis C. Lisa currently Coordinates the Outreach Hepatitis C Treatment Peer Education & Support Project at Hepatitis SA and has lived experience of hepatitis C. Having lived with the virus for approximately 27 years, Lisa was eager to commence the Direct Acting Anti-viral treatment for Genotype 3 and completed 12 weeks of treatment in 2016, with a successful result.

Sharon Hutchinson -Sharon Hutchinson is a Professor of Epidemiology and Population Health at Glasgow Caledonian University and holds an honorary appointment at Health Protection Scotland. She has over 20 years experience in conducting epidemiological research to inform on the design and impact of public health interventions. Authoring over 180 publications and PI/co-I on grants worth over £15 million, she leads a broad translational research programme on the prevention, diagnosis, and treatment of hepatitis C (HCV) and other blood-borne viruses. Her research provided the key evidence to guide a public health response to HCV in Scotland, which culminated in Scottish Government investing significantly in their Action Plan (£100 million during 2008-15). The evidenced-based National Plan was the stimulus for WHO and the World Hepatitis Alliance staging their inaugural World Hepatitis Summit (involving governments and civil society representatives from over 80 countries) in Glasgow during 2015.

Professor Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 20 years. He has developed extensive national and international collaborations, and is internationally recognized in the areas of HCV natural history and epidemiology, therapeutic strategies for acute and chronic HCV infection, particularly among people who inject drugs, and HCV elimination strategies.

Stuart Loveday is the CEO of Hepatitis NSW, Australia's first community based organisation and health promotion charity working for and on behalf of people with viral hepatitis. He is a former President and was a founding Board of Hepatitis Australia. Having worked in the hepatitis sector for almost 25 years, Stuart will be stepping down from his role in October 2019.

Su Wang, MD MPH is an internal medicine physician and Medical Director of the Center for Asian Health at Saint Barnabas Medical Center in New Jersey, USA. She is living with hepatitis B and is President-Elect of the World Hepatitis Alliance, a patient led global organization whose mission is to harness the power of people living with hepatitis to achieve its elimination. She is a leader of the NOhep Medical Visionary program and an advocate of primary-care based HBV/HCV care and innovative screening strategies to reach at-risk populations.